Skip to main content
. 2011 Jul 20;6(7):e22526. doi: 10.1371/journal.pone.0022526

Figure 4. Met-RANTES treatment at different doses modulate Th1, Th2, Th17 cytokine and osteclastogenic factor RANKL levels in experimental periodontitis.

Figure 4

C57Bl/6 mice were infected orally with AA, treated with met-RANTES at 0.5 and 5 mg doses or (V) veicule, (-) non treated and (C) control non-infected mice, sacrificed at day 30 post-infection and evaluated for levels of A) IFN-γ, a Th1 cytokine; B) IL-4, a Th2 cytokine; C) IL-17A, a Th17 cytokine and D) the major osteoclastogenic factor RANKL. Different italic low case letters represent statistically significant differences among the doses in the same experimental group (P<0.05; One-way ANOVA).